AuntMinnie

SEPTEMBER 30, 2024

A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. The researchers also tracked overall survival and rates of adverse events.

Radiation Oncology 119

Radiation Oncology Radiopharmaceuticals Radiation Clinic 119

Imaging Technology

AUGUST 29, 2023

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Pharmaceutical 97

Pharmaceutical Radiopharmaceuticals Clinic Medical 97

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. please insert video here.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

OCTOBER 2, 2024

Ultrasound model predicts liver disease progression. Assessment of Claimant, Clinical, and Financial Characteristics of Teleradiology Medical Malpractice Cases. Commercially Available Chest Radiograph AI Tools for Detecting Airspace Disease, Pneumothorax, and Pleural Effusion. SPECT/CT reveals heart’s response to tafamidis.

Digital Imaging and Communications in Medicine 143

Digital Imaging and Communications in Medicine X-ray MRI Hospital 143

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. This event marks a major milestone in the expansion of Blue Earth Diagnostics’ robust prostate cancer portfolio.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. “PET Clinical correlation, which may include histopathological evaluation, is recommended. Gauden , D.Phil.,

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We

Diagnose 52

Diagnose Diagnostic Disease Radiation 52